Salt Lake City, UT – May 23, 2024.
J3 Bioscience, Inc., a commercialization stage women’s health medical device company, today announced the appointment of three new members to its Board of Directors: John Fair, Dr. Keith Marmer, and Dr. Stephanie Singer.
John brings 20 years of experience in women’s health commercial strategy, fundraising and business development and currently serves as Global Head of Partnering & Corporate Development at Heranova Lifesciences. His insights and leadership will be invaluable as J3 Bioscience continues to commercialize its lead product, LivRing®.
Keith has 33 years’ experience in company formation, corporate strategy, leadership, business development, licensing, investment, technology development, patent strategy and clinical practice as an entrepreneur, executive and practitioner. He currently serves as Managing Partner of UVB Capital, a venture fund focused on partnering with early-stage life science companies. Prior to co-founding UVB Capital, Keith was Chief Innovation & Economic Engagement Officer at the University of Utah. His experience will be instrumental in guiding J3 Bioscience’s strategic direction and growth.
Stephanie is a Board-certified OB/GYN since 1999, specializing since 2019 solely in gynecology, minimally invasive gynecologic surgery and women’s health, with great emphasis on hormone balance, sexual health and healthy aging. Her expertise will be essential as J3 Bioscience commercializes its lead product and develops its follow-on products with its patented ring platform.
Dr. Jayne Carney has advised the Company that she will retire from the Board later this month concurrent with her 80th birthday. The Company extends its deepest gratitude to Jayne for her eight years of service on the Company’s Board of Directors.
“We are very excited to enhance our Board with these high caliber professionals at this pivotal time for the Company,” said R. Tyler McCabe, President and CEO of the Company. “Their contributions will help the Company achieve its strategic goals in many important ways.”
With the addition of these three new directors and the retirement of Dr. Carney, J3 Bioscience’s Board now consists of nine members with diverse backgrounds and expertise, further strengthening the company’s governance and strategic oversight.
About J3 Bioscience
J3 Bio is a commercialization stage women’s health medical device company. The Company’s lead product, known as the LivRing® (formerly termed VR101), is an FDA cleared (K203377), patented and unique lubricating intravaginal ring (IVR). It is designed to moisturize and lubricate the vagina, enhance the ease and comfort of intimate sexual activity, and supplement the body’s natural lubrication. It contains no hormones/drugs, is long-lasting (7 days each), and self-inserted weekly. It is the only IVR that provides long-lasting controlled-release of a moisturizing lubricant.
CONTACT:
R. Tyler McCabe, PhD
Chief Executive Officer, J3 Bioscience, Inc.
[email protected]